

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sarah S. BACUS et al
International Application No: PCT/US2003/012739
International Filing Date: 24 April 2003
Title: PREDICTIVE MARKERS IN CANCER THERAPY

BOX PCT (DO/EO/US)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FIRST PRELIMINARY AMENDMENT

Sir:

The above identified application is being transmitted herewith for entry into the U.S. National Phase under Chapter II of the PCT. For the purposes of adding the priority information, please amend the application as follows:

In the Abstract:

Please substitute the attached Abstract, which has been placed on a separate piece of paper according to US practice.

In the Specification:

On the first line of the specification, under the Title, please add:

--This application is filed pursuant to 35 U.S.C. § 371 as a United States National Phase Application of International Application No. PCT/US2003/012739 filed 24 April 2003, which claims priority from U.S. Provisional Application Nos. 60/389,795 filed 19 June 2002; 60/432,811 filed 11 December 2002; 60/432,943 filed 11 December 2002 and 60/451,978 filed 3 March 2003.--

Remarks:

Currently claims 1-26 are pending. Applicant has attached an abstract on a separate sheet of paper as required by US practice and have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Virginia G. Campen
Attorney for Applicants
Registration No. 37, 092

Date: March 29, 2005

GlaxoSmithKline
Corporate Intellectual Property Dept
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-1012/Fax: 919-483-7988